In previous studies, Mirdametinib showed growth-inhibitory and antiangiogenic effects on glioblastoma, non-small-cell lung cancer (NSCLC), and melanoma tumor progression by inhibiting mitogen-activated protein kinases (MAPKs) (Henderson et al., 2010). Here, WNK2 is linked to neoplasm.